Your browser is no longer supported. Please, upgrade your browser.
Settings
GRTS Gritstone Oncology, Inc. daily Stock Chart
GRTS [NASD]
Gritstone Oncology, Inc.
Index- P/E- EPS (ttm)-2.25 Insider Own7.27% Shs Outstand29.53M Perf Week-6.09%
Market Cap382.41M Forward P/E- EPS next Y-2.87 Insider Trans- Shs Float27.07M Perf Month13.10%
Income-64.80M PEG- EPS next Q-0.65 Inst Own70.00% Short Float9.37% Perf Quarter-11.18%
Sales1.20M P/S318.68 EPS this Y-51.40% Inst Trans0.01% Short Ratio18.57 Perf Half Y-16.40%
Book/sh5.03 P/B2.57 EPS next Y-8.70% ROA- Target Price23.50 Perf Year-
Cash/sh5.18 P/C2.50 EPS next 5Y- ROE- 52W Range9.66 - 32.90 Perf YTD-16.18%
Dividend- P/FCF- EPS past 5Y- ROI-41.10% 52W High-60.64% Beta-
Dividend %- Quick Ratio10.40 Sales past 5Y- Gross Margin- 52W Low34.06% ATR1.33
Employees113 Current Ratio10.40 Sales Q/Q- Oper. Margin- RSI (14)46.02 Volatility7.95% 9.52%
OptionableNo Debt/Eq0.07 EPS Q/Q-74.60% Profit Margin- Rel Volume1.79 Prev Close14.55
ShortableYes LT Debt/Eq0.07 EarningsMar 27 Payout- Avg Volume136.60K Price12.95
Recom2.00 SMA20-6.81% SMA501.99% SMA200-19.40% Volume242,393 Change-11.00%
Mar-15-19Initiated Raymond James Outperform
Mar-07-19Initiated H.C. Wainwright Buy $17
Oct-23-18Initiated Goldman Neutral $18
Oct-23-18Initiated BTIG Research Buy $26
Apr-23-19 08:08AM  The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale Benzinga -11.00%
Apr-22-19 04:28PM  Gritstone Oncology Announces Proposed Public Offering of Common Stock GlobeNewswire +5.90%
08:00AM  Gritstone Oncology Announces Clinical Acceleration of Off-The-Shelf Personalized Neoantigen Immunotherapy Program (SLATE) Following FDA Feedback GlobeNewswire
Apr-04-19 08:00AM  Gritstone Oncology Announces the Addition of Eugene Zhukovsky, Expert in Bispecific Biotherapeutics Development, to its Scientific Advisory Board GlobeNewswire +5.13%
Apr-03-19 04:00PM  Gritstone Oncology to Present at Needham Healthcare Conference GlobeNewswire
10:02AM  After inking lease with cancer-fighting company, this new East Bay biotech project is full American City Business Journals
Apr-02-19 04:00PM  Gritstone Oncology Presents Data at AACR Demonstrating MHC Class II Neoantigen Prediction with EDGE Significantly Outperforms Current Prediction Methods GlobeNewswire +9.51%
Mar-28-19 04:00PM  Gritstone Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights GlobeNewswire +5.47%
Mar-25-19 09:19AM  Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more American City Business Journals
Mar-21-19 04:00PM  Gritstone Oncology Announces First Patient Dosed in a Clinical Study Evaluating its Personalized Immunotherapy, GRANITE-001 GlobeNewswire
Mar-11-19 08:00AM  Gritstone Oncology Announces the Appointment of Technology Executive, Mike Forcht, as Senior Vice President of Human Resources to Support Vision for Growth GlobeNewswire
Mar-05-19 04:00PM  Gritstone Oncology to Present at Two Upcoming Investor Conferences in March GlobeNewswire -8.10%
Feb-27-19 06:12PM  Gritstone Oncology Announces Oral Presentation on MHC Class II Antigen Prediction at the AACR Annual Meeting in April 2019 GlobeNewswire
Feb-20-19 04:00PM  Gritstone Oncology to Present at Leerink Partners Annual Global Healthcare Conference GlobeNewswire
Jan-06-19 08:00AM  Gritstone Oncology Announces Updated Presentation Time at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-19 06:16PM  Gritstone Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-18 10:11AM  2019 biotech preview: Money is pouring into the Bay Area and so is Big Pharma American City Business Journals
Dec-20-18 04:00PM  Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001 for the Treatment of Colorectal Cancer GlobeNewswire -17.00%
Dec-19-18 04:17PM  TCR2 Therapeutics Announces Oncology Industry Leader and Expert Andrew Allen, M.D., Ph.D. Joins its Board of Directors PR Newswire -9.32%
Dec-17-18 11:00AM  Gritstone Oncology Announces Publication in Nature Biotechnology of Neoantigen Identification Capabilities of its Artificial Intelligence Platform, EDGE GlobeNewswire -7.08%
Dec-15-18 08:03AM  3 Biotechs Gilead Sciences Could Buy in March Motley Fool
Dec-13-18 05:18PM  Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay American City Business Journals
Dec-10-18 07:00AM  Gritstone Oncology Advances Solid Tumor Bispecific Antibody Program into Lead Optimization Phase; Appoints Vice President of Antibody Therapeutics to Spearhead GlobeNewswire -11.37%
Nov-26-18 02:03PM  Here's how much better insiders have profited from this year's IPO boom American City Business Journals
Nov-14-18 08:00AM  Gritstone Oncology Reports Third Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
Oct-01-18 01:34PM  24 Bay Area companies have gone public so far this year. Here's how they've done. American City Business Journals -5.55%
Sep-28-18 09:18AM  Gritstone Oncology expects to begin trading today, prices at $15 per share MarketWatch
07:24AM  [$$] Gritstone Oncology Prices Upsized IPO at Top of Range The Wall Street Journal
Sep-27-18 09:30PM  Gritstone Oncology Announces Pricing of Initial Public Offering GlobeNewswire
Sep-22-18 04:15PM  The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers Benzinga
Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.